These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37817256)

  • 1. Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience.
    Williams K; Tickler G; Valdivielso P; Alonso J; Vera-Llonch M; Cubells L; Acaster S
    Orphanet J Rare Dis; 2023 Oct; 18(1):316. PubMed ID: 37817256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.
    Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M
    Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study.
    Davidson M; Stevenson M; Hsieh A; Ahmad Z; Roeters van Lennep J; Crowson C; Witztum JL
    J Clin Lipidol; 2018; 12(4):898-907.e2. PubMed ID: 29784572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28.
    Kaiser K; Fox RS; Perschon C; Vera-Llonch M; Alonso J; Cubells L; Cella D
    Qual Life Res; 2023 Feb; 32(2):605-614. PubMed ID: 36310187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The burden of familial chylomicronemia syndrome in Canadian patients.
    Gaudet D; Stevenson M; Komari N; Trentin G; Crowson C; Hadker N; Bernard S
    Lipids Health Dis; 2020 Jun; 19(1):120. PubMed ID: 32487261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The burden of familial chylomicronemia syndrome from the patients' perspective.
    Gelrud A; Williams KR; Hsieh A; Gwosdow AR; Gilstrap A; Brown A
    Expert Rev Cardiovasc Ther; 2017 Nov; 15(11):879-887. PubMed ID: 28847199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volanesorsen for treatment of familial chylomicronemia syndrome.
    Lazarte J; Hegele RA
    Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS).
    Matza LS; Phillips GA; Howell TA; Ciffone N; Ahmad Z
    J Med Econ; 2020 Sep; 23(9):978-984. PubMed ID: 32479143
    [No Abstract]   [Full Text] [Related]  

  • 9. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
    Falko JM
    Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
    Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
    J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
    Baass A; Paquette M; Bernard S; Hegele RA
    J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
    Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
    J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two successful pregnancies -in patients taking Volanesorsen for familial chylomicronemia syndrome.
    Wanninayake S; Ochoa-Ferraro A; Patel K; Ramachandran R; Wierzbicki AS; Dawson C
    JIMD Rep; 2024 Jul; 65(4):249-254. PubMed ID: 38974616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of therapies for chylomicronemia.
    Shamsudeen I; Hegele RA
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span.
    Williams L; Rhodes KS; Karmally W; Welstead LA; Alexander L; Sutton L;
    J Clin Lipidol; 2018; 12(4):908-919. PubMed ID: 29804909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chylomicronemia.
    Navarro Hermoso A; Valdivielso P
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():75-79. PubMed ID: 34006359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides.
    Gouni-Berthold I
    J Endocr Soc; 2020 Feb; 4(2):bvz035. PubMed ID: 32083235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of a Fat-Restricted Diet in Four Patients with Familial Chylomicronemia Syndrome: A Long-Term Follow-Up Study.
    Thajer A; Skacel G; de Gier C; Greber-Platzer S
    Children (Basel); 2021 Nov; 8(11):. PubMed ID: 34828789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
    Esan O; Wierzbicki AS
    Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report.
    Makhmudova U; Schulze PC; Lorkowski S; März W; Geiling JA; Weingärtner O
    J Med Case Rep; 2024 Jun; 18(1):278. PubMed ID: 38872171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.